- Home
- HOUR vs ANL Comparison
HOUR vs ANL Comparison
Compare HOUR & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HOUR | ANL |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.5M | 52.0M |
| IPO Year | 2022 | 2023 |
Fundamental Metrics
Financial Performance| Metric | HOUR | ANL |
|---|---|---|
| Price | $1.99 | $1.38 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 42.1K | 28.5K |
| Earning Date | 11-12-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $140,790,433.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $83.79 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.10 | $0.88 |
| 52 Week High | $6.90 | $2.99 |
Technical Indicators
Market Signals| Indicator | HOUR | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 45.97 | 51.04 |
| Support Level | $1.99 | $0.88 |
| Resistance Level | $2.11 | $1.59 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 46.81 | 70.48 |
Price Performance
Historical ComparisonAbout HOUR Hour Loop Inc.
Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The Company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.